Beta
ManageSearchChatDiscover
114329

O6-MethylGuanine-DNA Methyltransferase (MGMT) Promoter Methylation Status Analysis in High-Grade Gliomas

Article

Last updated: 22 Jan 2023

OverviewSimilar Items

Subjects

-

Tags

Cellular and molecular targeting

Abstract

Background: The O6-methylguanine- DNA methyltransferase (MGMT) gene is frequently silenced by promoter hypermethylation in malignant gliomas and this has been pinpointed as an epigenetic mechanism reducing MGMT expression levels. The status of MGMT promoter hypermethylation and its relation to tumor progression in gliomas is under extensive study and previous studies have shown conflicting results on the significance of this epigenetic biomarker in relation to the tumor phenotype and clinical outcome. So, in our study, we assessed the role of the epigenetic biomarker; MGMT promoter methylation status, in high-grade glioma patients and correlated the results with the tumor phenotype and clinical outcome. Methods: The study included 40 high-grade glioma patients, assessed for MGMT promoter methylation status using methylation-specific PCR (MSP), and correlated the results with clinico-histopathological parameters and survival using appropriate statistical methodologies. Results: MGMT promoter methylation analysis revealed 65% of patients with the methylated promoter and 35% with unmethylated ones with no significant prognostic or predictive implications related to different treatment modalities (surgical, chemotherapy or radiation), recurrence rate, or overall survival. Conclusion: MGMT promoter methylation status role is not definitive in directing high-grade glioma patients' clinical decision making. Further studies are needed for investigating its role as an epigenetic marker in high-grade gliomas in Egyptian patients.

DOI

10.21608/jcbr.2020.32135.1043

Keywords

Alkylating agents, DNA Methylation, Epigenetics, gliomas, MGMT Promoter

Authors

First Name

Hoda

Last Name

Ibrahim

MiddleName

-

Affiliation

Genetics Unit, Department of Histology & Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt, Center of Excellence in Molecular & Cellular Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

hoda_ibrahim1@med.suez.edu.eg

City

Ismailia

Orcid

https://orcid.org/00

First Name

Amgad

Last Name

Matter

MiddleName

-

Affiliation

Neurosurgery Department, Faculty of Medicine, Suez Canal University

Email

amgadmatter@hotmail.com

City

-

Orcid

-

First Name

Azza

Last Name

Abdel-Aziz

MiddleName

-

Affiliation

Pathology Department, Faculty of Medicine, Mansoura University

Email

azza3a@mans.edu.eg

City

-

Orcid

-

First Name

Fouad

Last Name

Badr

MiddleName

-

Affiliation

Genetics Unit, Department of Histology & Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

fmbadr@gmail.com

City

-

Orcid

-

First Name

Eman

Last Name

Abdel-Moemen

MiddleName

-

Affiliation

Genetics Unit, Department of Histology & Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt, Center of Excellence in Molecular & Cellular Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

em.moemen1997@gmail.com

City

-

Orcid

-

Volume

5

Article Issue

1

Related Issue

23533

Issue Date

2021-03-01

Receive Date

2020-06-08

Publish Date

2021-03-01

Page Start

65

Page End

74

Print ISSN

2682-261X

Online ISSN

2682-2628

Article File

JCBR_Volume 5_Issue 1_Pages 65-74.pdf

PDF . 3.4MB

Link

https://jcbr.journals.ekb.eg/article_114329.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=114329

Order

7

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

International Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023